Site-dependent skeletal effects and fracture healing in female mice
Animal study · Female C57BL/6J wild-type mice, 12–14 weeks old at surgery, body weight >20 g; femoral osteotomy stabilized by external fixation. [1]
A single systemic treatment design examined fracture healing and the intact skeleton at multiple sacrifice times. Favorable day-28 repair outcomes coexisted with spinal trabecular bone loss. No human inference or quantified NET inhibition is established.
| Endpoint | Reported result | Reference |
|---|---|---|
| Callus structure and cartilage/mineralized area at days 7, 14 and 21 | reported direction No significant differences reported versus vehicle. | [1] |
| Day-28 callus bridging, maximum force and work to structural failure | reported direction Improved callus bridging and increased mechanical resistance; callus bone volume and tissue volume not significantly altered. | [1] |
| Day-21 spinal trabecular bone and contralateral femoral cortex | reported direction Spinal BV/TV decreased with increased osteoclast indices; femoral cortical thickness and endocortical osteoblast number increased. Distal femoral trabecular measures, cortical porosity and cortical osteoclast numbers were not significantly altered. | [1] |
| Day-21 callus osteoblast and osteoclast parameters | reported direction Osteoblast number and surface increased; osteoclast parameters not significantly altered. | [1] |
Conditions shared by the study groups
- Route
- Intraperitoneal injection
- Frequency
- Once daily
- Treatment course
- Started at surgery; continued to designated sacrifice time points. Adopted outcome measurements: days 7, 14, 21 and 28.
- Vehicle
- 0.9% saline
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Reboxetine mesylate versus saline 15 mg/kg (as reported; no salt-to-base conversion) | Vehicle injections (0.9% saline) under the same fracture model and perioperative treatment. | Improved late callus bridging/mechanics with unchanged early structural endpoints and adverse spinal trabecular effects; see measurements. | [1] |
- Reboxetine mesylate versus saline
- Model: Female C57BL/6J wild-type mice, 12–14 weeks old at surgery, body weight >20 g; femoral osteotomy stabilized by external fixation.
- Reported limits: No lot-specific composition or enantiomeric assay. Exact mechanical effect sizes not extracted from graphs.
Methods and source locations
Compound reported in the paper: Reboxetine mesylate; Compound label in the paper: AdooQ BioScience A11919; CAS 98769-84-7
Reported use of catalog A11919 in a female-mouse bone-repair model; no validation of current AdooQ lots, human healing, or isolated enantiomer potency.
Figures 2–5, associated Results and captions; key resources table; STAR Methods: Animal experiments, Materials, Surgery and treatment, Micro-computed tomography, Histomorphometry, Biomechanics, Quantification and statistical analysis; Limitations of the study
Callus structure and cartilage/mineralized area at days 7, 14 and 21: Micro-CT and Movat pentachrome histomorphometry; n = 6 mice per group and time point; unpaired two-tailed Student’s t tests. — Figures 3B and 4B, captions; corresponding Results; STAR Methods: Quantification and statistical analysis
Day-28 callus bridging, maximum force and work to structural failure: Blinded semiquantitative micro-CT bridging assessment; three-point bending; n = 6 mice per group. Figure 5D labels p = 0.002 for maximum force and p = 0.04 for work; no graph-derived effect sizes extracted. — Figure 5A–D and caption; Results: Reboxetine improves late-stage fracture healing; STAR Methods: Micro-computed tomography, Biomechanics
Day-21 spinal trabecular bone and contralateral femoral cortex: Histomorphometry and micro-CT; n = 6 mice per group. Boxplots: median, 25th/75th quantiles, minimum/maximum whiskers. — Figure 2A–F and caption; Results: Systemic reboxetine treatment exerts distinct effects in the non-fractured skeleton
Day-21 callus osteoblast and osteoclast parameters: Histomorphometry; n = 6 mice per group; unpaired two-tailed Student’s t tests. — Figure 4C–D and caption; corresponding Results
Reboxetine mesylate versus saline · STAR Methods: Animal experiments, Materials, Surgery and treatment; Figures 2–5 and captions